Dual-Peak Lorentzian CEST MRI for antiretroviral drug brain distribution
Author:
Liu Yutong12ORCID, Gauthier Gabriel C.2, Gendelman Howard E.1, Bade Aditya N.1
Affiliation:
1. Department of Pharmacology and Experimental Neuroscience , University of Nebraska Medical Center , Omaha , NE , USA 2. Department of Radiology , University of Nebraska Medical Center , Omaha , NE , USA
Abstract
Abstract
Objectives
Spatial–temporal biodistribution of antiretroviral drugs (ARVs) can now be achieved using MRI by utilizing chemical exchange saturation transfer (CEST) contrasts. However, the presence of biomolecules in tissue limits the specificity of current CEST methods. To overcome this limitation, a Lorentzian line-shape fitting algorithm was developed that simultaneously fits CEST peaks of ARV protons on its Z-spectrum.
Case presentation
This algorithm was tested on the common first line ARV, lamivudine (3TC), that has two peaks resulting from amino (–NH2) and hydroxyl (–OH) protons in 3TC. The developed dual-peak Lorentzian function fitted these two peaks simultaneously, and used the ratio of –NH2 and –OH CEST contrasts as a constraint parameter to measure 3TC presence in brains of drug-treated mice. 3TC biodistribution calculated using the new algorithm was compared against actual drug levels measured using UPLC-MS/MS. In comparison to the method that employs the –NH2 CEST peak only, the dual-peak Lorentzian fitting algorithm showed stronger correlation with brain tissue 3TC levels, signifying estimation of actual drug levels.
Conclusions
We concluded that 3TC levels can be extracted from confounding CEST effects of tissue biomolecules resulting in improved specificity for drug mapping. This algorithm can be expanded to measure a variety of ARVs using CEST MRI.
Publisher
Walter de Gruyter GmbH
Reference46 articles.
1. Dadfar, SM, Roemhild, K, Drude, NI, von Stillfried, S, Knüchel, R, Kiessling, F, et al.. Iron oxide nanoparticles: diagnostic, therapeutic and theranostic applications. Adv Drug Deliv Rev 2019;138:302–25. https://doi.org/10.1016/j.addr.2019.01.005. 2. Lux, F, Sancey, L, Bianchi, A, Crémillieux, Y, Roux, S, Tillement, O. Gadolinium-based nanoparticles for theranostic MRI-radiosensitization. Nanomedicine 2015;10:1801–15. https://doi.org/10.2217/nnm.15.30. 3. Zhu, L, Zhou, Z, Mao, H, Yang, L. Magnetic nanoparticles for precision oncology: theranostic magnetic iron oxide nanoparticles for image-guided and targeted cancer therapy. Nanomedicine 2017;12:73–87. https://doi.org/10.2217/nnm-2016-0316. 4. Bailly, C, Cléry, PF, Faivre-Chauvet, A, Bourgeois, M, Guérard, F, Haddad, F, et al.. Immuno-PET for clinical theranostic approaches. Int J Mol Sci 2016;18:57. https://doi.org/10.3390/ijms18010057. 5. Bodet-Milin, C, Bailly, C, Touchefeu, Y, Frampas, E, Bourgeois, M, Rauscher, A, et al.. Clinical results in medullary thyroid carcinoma suggest high potential of pretargeted immuno-PET for tumor imaging and theranostic approaches. Front Med 2019;6:124. https://doi.org/10.3389/fmed.2019.00124.
|
|